WO2008125116A3 - Upar inhibition - Google Patents

Upar inhibition Download PDF

Info

Publication number
WO2008125116A3
WO2008125116A3 PCT/DK2008/050075 DK2008050075W WO2008125116A3 WO 2008125116 A3 WO2008125116 A3 WO 2008125116A3 DK 2008050075 W DK2008050075 W DK 2008050075W WO 2008125116 A3 WO2008125116 A3 WO 2008125116A3
Authority
WO
WIPO (PCT)
Prior art keywords
aptamers
present
prevention
proteolytic activity
relates
Prior art date
Application number
PCT/DK2008/050075
Other languages
French (fr)
Other versions
WO2008125116A2 (en
Inventor
Joergen Kjems
Daniel Miotto Dupont
Peter A Andreasen
Original Assignee
Univ Aarhus
Joergen Kjems
Daniel Miotto Dupont
Peter A Andreasen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aarhus, Joergen Kjems, Daniel Miotto Dupont, Peter A Andreasen filed Critical Univ Aarhus
Publication of WO2008125116A2 publication Critical patent/WO2008125116A2/en
Publication of WO2008125116A3 publication Critical patent/WO2008125116A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification

Landscapes

  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to aptamers capable of binding to a receptor-binding form of urokinase-type plasminogen activator protein, u-PA. Furthermore, the present invention relates to use of the aptamers for prevention of u-PA-mediated proteolytic activity at the cell surface for the preparation of a composition for preventing or counteracting proteolytic activity on the surface of a cell. The aptamers of the present invention may additionally be used as imaging agents or used for the treatment or prevention of cancer and/or metastatic spread. Within the scope of the present invention is also pharmaceutical compositions and diagnostic kits comprising aptamers.
PCT/DK2008/050075 2007-03-31 2008-03-28 Upar inhibition WO2008125116A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200700506 2007-03-31
DKPA200700506 2007-03-31
DKPA200701559 2007-11-01
DKPA200701559 2007-11-01

Publications (2)

Publication Number Publication Date
WO2008125116A2 WO2008125116A2 (en) 2008-10-23
WO2008125116A3 true WO2008125116A3 (en) 2009-03-12

Family

ID=39864405

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2008/050075 WO2008125116A2 (en) 2007-03-31 2008-03-28 Upar inhibition

Country Status (1)

Country Link
WO (1) WO2008125116A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011341018A1 (en) * 2010-12-10 2013-07-25 Merck Patent Gmbh Aptamer labeled with F-19 nucleus for targeted molecular imaging by MRI
PT2872157T (en) 2012-07-12 2020-04-30 Hangzhou Dac Biotech Co Ltd Conjugates of cell binding molecules with cytotoxic agents
CN105849086B (en) 2012-11-24 2018-07-31 杭州多禧生物科技有限公司 Hydrophily chain junctor and its application on drug molecule and cell-binding molecules conjugation reaction
CN106414465B (en) 2014-02-28 2021-11-16 杭州多禧生物科技有限公司 Charged linkers and their use in conjugation reactions
EP3319936A4 (en) 2015-07-12 2019-02-06 Suzhou M-conj Biotech Co., Ltd. Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CN106497919A (en) 2016-11-02 2017-03-15 四川大学 A kind of DNA tetrahedrons of aptamer AS1411 modifications and preparation method thereof
KR20220147719A (en) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
WO2019165105A1 (en) * 2018-02-26 2019-08-29 The Board Of Trustees Of The Leland Stanford Junior University Ligands of the urokinase receptor and their use in treating, detecting, and imaging cancer
IL289458A (en) 2019-06-29 2022-07-01 Hangzhou Dac Biotech Co Ltd Cell-binding molecule-tubulysin derivative conjugate and preparation method therefor
CN111453729B (en) * 2019-08-26 2021-06-18 山东大学 Method for preparing super activated carbon with assistance of ultrasonic waves and application of super activated carbon
EP4194555A1 (en) * 2021-12-09 2023-06-14 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Dna aptamers inhibiting binding of urokinase type plasminogen activator (upa) with urokinase type plasminogen activator receptor (upar) and inhibiting upa activity

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HAMULA C.L.A. ET AL.: "Selection and analytical applications of Aptamers", TRENDS IN ANALYTICAL CHEMISTRY, vol. 25, no. 7, 2006, pages 681 - 691, XP002509244 *
JAYASENA S.D.: "Aptamers: an emerging class of molecules that rival antibodies in diagnostics", CLINICAL CHEMISTRY, vol. 45, no. 9, 1999, pages 1628 - 1650, XP002509245 *
SCHMITT M. ET AL.: "The Urokinase Plasminogen Activator system as a novel target for tumour therapy", FIBRINOLYSIS & PROTEOLYSIS, vol. 14, no. 2/3, 2000, pages 114 - 132, XP002509198 *
SCHWEINITZ A. ET AL.: "Design of novel and selective inhibitors of urokinase-type Plasminogen Activator with improved pharmakokinetic properties for use as antimetastatic agents", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 32, 6 August 2004 (2004-08-06), pages 33613 - 33622, XP002509197 *
SKRYPINA N.A. ET AL.: "In vitro selection of single-stranded DNA aptamers that bind human pro-urokinase", NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, vol. 23, no. 6-7, October 2004 (2004-10-01), pages 891 - 893, XP008100024 *
ULRICH H.: "DNA and RNA Aptamers as modulators of protein function", MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS LTD, BUSSUM, NL, vol. 1, no. 2, 1 March 2005 (2005-03-01), pages 199 - 208, XP001248936, ISSN: 1573-4064 *
ULRICH H.: "RNA Aptamers: from basic science towards therapy", HANDBOOK OF EXPERIMENTAL PHARMACOLOGY, vol. 173, 2006, pages 305 - 326, XP001249105 *

Also Published As

Publication number Publication date
WO2008125116A2 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
WO2008125116A3 (en) Upar inhibition
EP1859793A4 (en) Novel combinational use of sulfonamide compound
TN2009000137A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
CL2007002017A1 (en) COMPOUNDS DERIVED FROM [4,5 '] - BIPIRIMIDINIL-6,4'-DIAMINE; PHARMACEUTICAL COMPOSITION; AND USE AS AN INHIBITOR OF THE ACTIVITY OF CINASA IN CANCER DE VEJIGA, CANCER CERVICAL AND MIELOMA MULTIPLE.
WO2008028965A3 (en) Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
MY143795A (en) Tetrahydropyridoindole derivatives
CL2011001863A1 (en) Compounds derived from phenylaminopyrimidines, anaplastic lymphoma kinase inhibitors; pharmaceutical composition; pharmacological combination; and its use in the treatment of proliferative disorders such as lymphoma, osteosarcoma, melanoma or breast, renal and prostate tumor, among others (divisional application 3552-07).
BRPI0806531A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, THERAPEUTIC AGENT, AND USE OF THE COMPOUND.
WO2006091395A3 (en) Inhibitors of akt activity
IL228952B (en) Use of compositions comprising ferric citrate for the preparation of medicaments for reducing serum phosphate levels
WO2006135627A3 (en) Inhibitors of akt activity
WO2010001169A3 (en) Chemical compounds 251
WO2009031106A3 (en) Use of a combination of hesperidin and of a microorganism for influencing the barrier function of the skin
BR0312573A (en) Phenyl- [4- (3-phenyl-1h-pyrazol-4-yl) -pyrimidin-2-yl] -amine derivatives
WO2009114725A3 (en) Mobilization op hematopoietic stem cells using cdc42 inhibitors
WO2006110638A3 (en) Inhibitors of akt activity
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
CL2007003038A1 (en) COMPOUNDS DERIVED FROM 2-PHENYL-6-AMINOCARBONIL-PYRIMIDINE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF OCLUSIVE VASCULAR DISORDERS.
WO2005099749A3 (en) Methods for controlling angiogenesis and cell proliferation
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
MY148647A (en) Pharmaceutical compositions comprising a camtothecin derivative
TW200621773A (en) Bicyclononene derivatives
CL2008002082A1 (en) Compounds derived from 6-phenyl-1h-imidazo [4,5-c] pyridine-4-carbonitrile, inhibitors of cathepsin s and cathepsin k; pharmaceutical composition; and use in the treatment of osteoporosis, atherosclerosis, inflammation, among other diseases.
WO2007010394A3 (en) Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08715629

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08715629

Country of ref document: EP

Kind code of ref document: A2